WO2001065994A2 - Method of and kit for assessing responsiveness of cancer patients to antifolate chemotherapy - Google Patents
Method of and kit for assessing responsiveness of cancer patients to antifolate chemotherapy Download PDFInfo
- Publication number
- WO2001065994A2 WO2001065994A2 PCT/IL2001/000212 IL0100212W WO0165994A2 WO 2001065994 A2 WO2001065994 A2 WO 2001065994A2 IL 0100212 W IL0100212 W IL 0100212W WO 0165994 A2 WO0165994 A2 WO 0165994A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- rfc
- transport
- mtx
- folic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Abstract
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/936,764 US20040101834A1 (en) | 2001-03-06 | 2001-03-06 | Method of and kit for assessing responsiveness of cancer patients to antifolate chemotherapy |
AU2001240998A AU2001240998A1 (en) | 2000-03-06 | 2001-03-06 | Method of and kit for assessing responsiveness of cancer patients to antifolate chemotherapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51967300A | 2000-03-06 | 2000-03-06 | |
US09/519,673 | 2000-03-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001065994A2 true WO2001065994A2 (en) | 2001-09-13 |
WO2001065994A3 WO2001065994A3 (en) | 2002-01-17 |
Family
ID=24069301
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2001/000212 WO2001065994A2 (en) | 2000-03-06 | 2001-03-06 | Method of and kit for assessing responsiveness of cancer patients to antifolate chemotherapy |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001240998A1 (en) |
WO (1) | WO2001065994A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1556515A1 (en) * | 2002-10-10 | 2005-07-27 | Precision Therapeutics Inc. | Methods for assessing efficacy of chemotherapeutic agents |
EP1668337A2 (en) * | 2003-08-29 | 2006-06-14 | Prometheus Laboratories, Inc. | Methods for optimizing clinical responsiveness to methotrexate therapy using metabolite profiling and pharmacogenetics |
WO2010055525A1 (en) * | 2008-11-17 | 2010-05-20 | Technion Research & Development Foundation Ltd. | Method for predicting a patient's responsiveness to anti-folate therapy |
WO2011005504A1 (en) * | 2009-06-22 | 2011-01-13 | Precision Therapeutics, Inc. | Methods for predicting a cancer patient's response to antifolate therapy |
US7972769B2 (en) | 1996-07-12 | 2011-07-05 | Precision Therapeutics, Inc. | Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays |
-
2001
- 2001-03-06 AU AU2001240998A patent/AU2001240998A1/en not_active Abandoned
- 2001-03-06 WO PCT/IL2001/000212 patent/WO2001065994A2/en active Search and Examination
Non-Patent Citations (4)
Title |
---|
GUO W. ET AL.: 'Mechanisms of methotrexate resistance in osteosarcoma' CLINICAL CANCER RESEARCH vol. 5, March 1999, pages 621 - 627, XP002944952 * |
JANSEN G. ET AL.: 'A structurally altered human reduced folate carrier with increased folic acid trransport mediates a novel mechanism of antifolate resistance' JOURNAL OF BIOLOGICAL CHEMISTRY vol. 273, no. 46, 13 November 1998, pages 30189 - 30198, XP002944953 * |
ROY K. ET AL.: 'A single amino acid difference within the folate transporter encoded by the murine RFC-1 gene selectivity alters its interaction with folate analogues' JOURNAL OF BIOLOGICAL CHEMISTRY vol. 273, no. 5, 30 January 1998, pages 2526 - 2531, XP002944954 * |
TAKEMURA Y. ET AL.: 'Biological activity and intracellular metabolism of ZD1694 in human leukemia cell lines with different resistance mechanisms to antifolate drugs' JAPANESE JOURNAL OF CANCER RESEARCH vol. 87, July 1996, pages 773 - 780, XP002944955 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7575868B2 (en) | 1996-07-12 | 2009-08-18 | Precision Therapeutics, Inc. | Methods for assessing efficacy of chemotherapeutic agents |
US7972769B2 (en) | 1996-07-12 | 2011-07-05 | Precision Therapeutics, Inc. | Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays |
EP1556515A1 (en) * | 2002-10-10 | 2005-07-27 | Precision Therapeutics Inc. | Methods for assessing efficacy of chemotherapeutic agents |
EP1556515A4 (en) * | 2002-10-10 | 2007-11-07 | Precision Therapeutics Inc | Methods for assessing efficacy of chemotherapeutic agents |
US7829288B2 (en) | 2002-10-10 | 2010-11-09 | Precision Therapeutics, Inc. | Methods for assessing efficacy of chemotherapeutic agents |
US8039213B2 (en) | 2002-10-10 | 2011-10-18 | Precision Therapeutics, Inc. | Methods for assessing efficacy of chemotherapeutic agents |
EP1668337A2 (en) * | 2003-08-29 | 2006-06-14 | Prometheus Laboratories, Inc. | Methods for optimizing clinical responsiveness to methotrexate therapy using metabolite profiling and pharmacogenetics |
EP1668337A4 (en) * | 2003-08-29 | 2008-11-05 | Prometheus Lab Inc | Methods for optimizing clinical responsiveness to methotrexate therapy using metabolite profiling and pharmacogenetics |
US7582282B2 (en) | 2003-08-29 | 2009-09-01 | Prometheus Laboratories Inc. | Methods for optimizing clinical responsiveness to methotrexate therapy using metabolite profiling and pharmacogenetics |
WO2010055525A1 (en) * | 2008-11-17 | 2010-05-20 | Technion Research & Development Foundation Ltd. | Method for predicting a patient's responsiveness to anti-folate therapy |
WO2011005504A1 (en) * | 2009-06-22 | 2011-01-13 | Precision Therapeutics, Inc. | Methods for predicting a cancer patient's response to antifolate therapy |
Also Published As
Publication number | Publication date |
---|---|
WO2001065994A3 (en) | 2002-01-17 |
AU2001240998A1 (en) | 2001-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kluijtmans et al. | Defective cystathionine beta-synthase regulation by S-adenosylmethionine in a partially pyridoxine responsive homocystinuria patient. | |
Azzedine et al. | Mutations in MTMR13, a new pseudophosphatase homologue of MTMR2 and Sbf1, in two families with an autosomal recessive demyelinating form of Charcot-Marie-Tooth disease associated with early-onset glaucoma | |
Malkin et al. | Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms | |
Simon et al. | Gitelman's variant of Barter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na–Cl cotransporter | |
Grandchamp | Acute intermittent porphyria | |
Vulliamy et al. | The molecular basis of glucose-6-phosphate dehydrogenase deficiency | |
Sarfarazi et al. | Assignment of a locus (GLC3A) for primary congenital glaucoma (Buphthalmos) to 2p21 and evidence for genetic heterogeneity | |
US6824972B2 (en) | Diagnosis and treatment of medical conditions associated with defective NFkappa B(NF-κB) activation | |
Perrault et al. | A retGC-1 mutation in autosomal dominant cone-rod dystrophy | |
Rothem et al. | Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines | |
Barker et al. | A mutation causing Alport syndrome with tardive hearing loss is common in the western United States. | |
Nesterova et al. | Overexpresson of RIIβ, Regulatory Subunit of Protein Kinase A in Human Colon Carcinoma Cell Induces Growth Arrest and Phenotypic Changes that are Abolished by Site‐Directed Mutation of RIIβ | |
CA2454637A1 (en) | Use of irinotecan for improved treatment of cancer based on mdr1 | |
Jedlickova et al. | Search for genetic determinants of individual variability of the erythropoietin response to high altitude | |
Casula et al. | BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study | |
Valente et al. | PARK6 is a common cause of familial parkinsonism | |
Kennan et al. | A novel Asp380Ala mutation in the GLC1A/myocilin gene in a family with juvenile onset primary open angle glaucoma. | |
WO2001065994A2 (en) | Method of and kit for assessing responsiveness of cancer patients to antifolate chemotherapy | |
Garcia-Hoyos et al. | Mutation analysis at codon 838 of the Guanylate Cyclase 2D gene in Spanish families with autosomal dominant cone, cone-rod, and macular dystrophies | |
US20070254288A1 (en) | Diagnostic methods for pain sensitivity and chronicity and for tetrahydrobiopterin-related disorders | |
Van Kuilenburg et al. | Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene | |
EP1625231A1 (en) | Diagnosis and prediction of parkinson's disease | |
EP0514490A1 (en) | Allelic association of the human dopamine (d 2?) receptor gene in compulsive disorders such as alcoholism. | |
Royle | 7 The Proterminal Regions and Telomeres of Human Chromosomes | |
Ohye et al. | Genomic organization and chromosomal localization of the human sepiapterin reductase gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09936764 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) |